PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
OMB COMB
OMB
OMB
OMB
OMB

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

Complete if Known				
Application Number	10/613,783			
Filing Date	July 3, 2003			
First Named Inventor	Michel PAIRET et al			
Art Unit	To be assigned			
Examiner Name	To be assigned			
Attorney Docket Number	1/1192-1-C1			

U.S. PATENT DOCUMENTS							
		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
ESO		us- 2002/0052312 A	05/02/2002	BACH, Mark A. et al	rigules Appear		
ESQ		us- 5,610,163	03/11/1997	R. Banholzer et al.			
		US-					
		us-					
		US-					
		US-					
		US-					
		US-			***************************************		
		US-					
		UŞ-		The state of the s			
		US-					
		US-					
		US-		Andrews () () () () () () () () () (
		US-					
		US-	***************************************				
		US-		The Property of the Property o			
		US-					
		US-					
		US-	~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				
		US-					

	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 9 (# Known) WO 01 78741 A1 - WO 02 09689 A1 -	10/25/2001	Name of Patentee or Applicant of Cited Document Glaxo Group Ltd.	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ¢
ESO					
	WO 02 09689 A1 -	00/07/0000			
	110 02 00000 / (1	02/07/2002	Smithkline Beecham		
ESO	WO 01 57025 A1 -	08/09/2001	Pfizer Products Inc.		-
	WO 01 46151 A1	06/28/2001	Merck Frosst Canada		
ESO	EP 1 040 829 A2 /	10/04/2000	Pfizer Inc.		
_ESO	WO 00/35428	06/22/2000	Boehringer Ingelheim Pharma KG		
					-

Examiner Signature	/Eric Olson/	Date Considered	08/22/2006

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute fo	or form 1449B/PTO			Complete if Known		
				Application Number	10/613,783	
INFOR		DIS	CLOSURE	Filing Date	July 3, 2003	
STATI	EMENT RY	γ Δ	PPLICANT	First Named Inventor	Michel PAIRET et al	
ייאוט		. ^	LICAN	Group Art Unit	To be assigned	
(use as many sheets as necessary)				Examiner Name	To be assigned	
Sheet	2	of	2	Attorney Docket Number	1/1192-1-C1	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue outper(s), outplisher, city and/or country where published.	T2			
ESO		DISSE, B. et al: "BA 679 BR, A Novel Long-Acting Anticholinergic Bronchodilator: LIFE SCIENCES, Pergamon Press, Oxford, GB, Bd. 5/6, Nr. 52, 1993, Seiten 537-544, XP008002589 ISSN: 0024-3205				
ESO	V	BARNES, P.J.: "Nonantimicrobial Aspects of Therapy" SEMINARS IN RESPIRATORY INFECTIONS, Grune and Stratton, Orlando, US, Bd. 15, Nr. 1, 2000, Selten 52-58 XP000911165, ISSN: 0882-0546, Selte 53, Spalte 1, Absatz 2 - Selte 56, Spalte 1, Zelle 20-40				
ESO		TAVAKKOLI, A., REES, P.J.: "Drug Treatment of Asthma in the 1990s: Achievements and New Strategies" DRUGS, Bd. 57, Nr. 1, 1999, Seiten 1-8 XP001098314 ISSN: 0012-6667 Seite 3, Spalte 2, Abstaz 2; Seite 4, Spalte 2, Abstaz 2				
ESO	<i>ر</i>	DATA BASE WPI Derwent Publications Ltd., London, GB; AN 2001-626119 XP002212897 MATSUMOTO, Tatsumi, TARUI, Naoki et al.: "New and Know Furoisoquinoline Compounds as Phosphodiesterase IV Inhibitors"				
a a square 646 accompanion 2100 a						
			1			

Examiner	/Eric Olson/	Date	08/22/2006
Signature		Considered	00/22/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



[.] Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.